Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-ALCAM, CX-191 Vector   (CAT#: GTVCR-WQ1098MR)

This product GTVCR-WQ1098MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting ALCAM. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Humanized
RefSeq NM_001243280.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 214
UniProt ID Q13740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-ALCAM, CX-191 Vector (GTVCR-WQ1098MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ161MR IVTScrip™ pSP6-VEE-mRNA-Anti-EGFR, ABBV-221 Vector Vector ABBV-221
GTVCR-WQ1448MR IVTScrip™ pT7-VEE-mRNA-Anti-AXL, HuMax-AXL-ADC Vector Vector HuMax-AXL-ADC
GTVCR-WQ590MR IVTScrip™ pSP6-VEE-mRNA-Anti-pcrV, BA1126 Vector Vector BA1126
GTVCR-WQ1982MR IVTScrip™ pSP6-VEE-mRNA-Anti-LAG3, MK-4280 Vector Vector MK-4280
GTVCR-WQ1623MR IVTScrip™ pT7-VEE-mRNA-Anti-KLRK1, JNJ-64304500 Vector Vector JNJ-64304500
GTVCR-WQ2486MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD33, SGN-CD33A Vector Vector SGN-CD33A
GTVCR-WQ1358MR IVTScrip™ pSP6-VEE-mRNA-Anti-C5, h5G1.1HuG2/G4 Vector Vector h5G1.1HuG2/G4
GTVCR-WQ1876MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF18, MEDI-1873 Vector Vector MEDI-1873
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW